2022
Breast Cancer Patients: Who Would Benefit from Neoadjuvant Chemotherapies?
Yao L, Jia G, Lu L, Ma W. Breast Cancer Patients: Who Would Benefit from Neoadjuvant Chemotherapies? Current Oncology 2022, 29: 4902-4913. PMID: 35877249, PMCID: PMC9320700, DOI: 10.3390/curroncol29070389.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsFemaleHumansLymphocytes, Tumor-InfiltratingNeoadjuvant TherapyConceptsNeoadjuvant chemotherapyBreast cancer patientsCancer patientsEfficacy of NACHuman leukocyte antigen-DR isotypeInitiation of therapyTumor-infiltrating lymphocytesBenefits of treatmentTumor-associated macrophagesOncotype DXMolecular testingPatientsDecreased levelsCancer cellsChemotherapyTreatmentMammaPrintSurgeryLymphocytesTherapyTumorsMacrophages
2011
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer
Ratner ES, Keane FK, Lindner R, Tassi RA, Paranjape T, Glasgow M, Nallur S, Deng Y, Lu L, Steele L, Sand S, Muller RU, Bignotti E, Bellone S, Boeke M, Yao X, Pecorelli S, Ravaggi A, Katsaros D, Zelterman D, Cristea MC, Yu H, Rutherford TJ, Weitzel JN, Neuhausen SL, Schwartz PE, Slack FJ, Santin AD, Weidhaas JB. A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. Oncogene 2011, 31: 4559-4566. PMID: 22139083, PMCID: PMC3342446, DOI: 10.1038/onc.2011.539.Peer-Reviewed Original ResearchMeSH Keywords3' Untranslated RegionsAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBRCA1 ProteinBRCA2 ProteinCarboplatinCell Line, TumorCell SurvivalDrug Resistance, NeoplasmFemaleGenotypeHumansKaplan-Meier EstimateMiddle AgedMultivariate AnalysisMutationNeoplasms, Glandular and EpithelialOvarian NeoplasmsPaclitaxelPolymorphism, Single NucleotidePrognosisProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)Ras ProteinsRNA InterferenceTreatment OutcomeConceptsEpithelial ovarian cancerEOC patientsKRAS-variantOvarian cancerPoor outcomeCancer riskTumor biologyPlatinum resistanceComplete clinical dataBiomarkers of outcomeDirect targetingEOC cell growthKnown BRCA mutationsFuture treatment approachesSubset of tumorsPlatinum chemotherapy resistanceCell linesNeoadjuvant chemotherapyBRCA mutationsClinical dataTreatment approachesChemotherapy resistanceKRAS oncogeneMultivariate analysisPatients
2008
Klotho Expression in Epithelial Ovarian Cancer and its Association with Insulin-Like Growth Factors and Disease Progression
Lu L, Katsaros D, Wiley A, de la Longrais IA, Puopolo M, Yu H. Klotho Expression in Epithelial Ovarian Cancer and its Association with Insulin-Like Growth Factors and Disease Progression. Cancer Investigation 2008, 26: 185-192. PMID: 18259951, DOI: 10.1080/07357900701638343.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCystadenocarcinoma, SerousDisease ProgressionEpithelial CellsFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticGlucuronidaseHumansInsulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor IInsulin-Like Growth Factor IIKlotho ProteinsMiddle AgedNeoplasm StagingOvarian NeoplasmsPrognosisReverse Transcriptase Polymerase Chain ReactionRNA, NeoplasmSurvival RateConceptsEpithelial ovarian cancerKlotho expressionOvarian cancer progressionDisease progressionOvarian cancerCox proportional hazards regression modelTumor tissueProportional hazards regression modelsCancer progressionInsulin-like growth factorResidual tumor sizeAction of IGFOvarian cancer patientsExpression of IGFHazards regression modelsOvarian cancer prognosisEpithelial ovarian cancer progressionExpression of totalFresh tumor tissueWarrants further elucidationUnderwent surgeryIGFBP-3Patient ageClinical followTumor histology
2007
Expression of MDR1 in epithelial ovarian cancer and its association with disease progression.
Lu L, Katsaros D, Wiley A, Rigault de la Longrais IA, Puopolo M, Yu H. Expression of MDR1 in epithelial ovarian cancer and its association with disease progression. Oncology Research Featuring Preclinical And Clinical Cancer Therapeutics 2007, 16: 395-403. PMID: 17913048, DOI: 10.3727/000000006783980892.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsATP Binding Cassette Transporter, Subfamily B, Member 1Biomarkers, TumorBRCA1 ProteinCyclin-Dependent Kinase Inhibitor p16Disease ProgressionDrug Resistance, MultipleEstrogen Receptor alphaFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticHumansInsulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor IIMiddle AgedNeoplasm StagingNeoplasms, Cystic, Mucinous, and SerousOvarian NeoplasmsPrognosisRetrospective StudiesReverse Transcriptase Polymerase Chain ReactionRNA, MessengerRNA, NeoplasmSurvival AnalysisTreatment OutcomeConceptsMDR1 expressionClinicopathological parametersDisease progressionOvarian cancer cohortEpithelial ovarian cancerOvarian cancer prognosisOvarian cancer treatmentOvarian cancer progressionExpression of MDR1Ovarian tumor samplesOverall survivalPatient ageOvarian tumorsIGF-IIQuantitative real-time PCROvarian cancerCancer cohortReal-time PCRIndependent markerCancer prognosisDrug resistanceTumor samplesCancer treatmentCancer progressionERalpha